Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enliven Therapeutics ( (ELVN) ) has issued an announcement.
Enliven Therapeutics, Inc. held its Annual Meeting of Stockholders on June 24, 2025, where several key proposals were voted upon. The election of three Class II Directors resulted in the appointment of Rahul D. Ballal, Ph.D., Jake Bauer, M.B.A., and Andrew Phillips, Ph.D., to serve until the 2028 annual meeting. Additionally, the stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ELVN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Enliven Therapeutics stock, see the ELVN Stock Forecast page.
Spark’s Take on ELVN Stock
According to Spark, TipRanks’ AI Analyst, ELVN is a Underperform.
Enliven Therapeutics’ stock is challenged by its early-stage financial profile with no revenue and ongoing losses. Despite strong liquidity, the reliance on external financing and lack of profitability weigh heavily. Technical indicators reinforce a cautious approach, as the stock shows bearish trends. Valuation metrics further reflect the typical risk profile of a biotech company in development.
To see Spark’s full report on ELVN stock, click here.
More about Enliven Therapeutics
Average Trading Volume: 445,144
Technical Sentiment Signal: Buy
Current Market Cap: $1.2B
For a thorough assessment of ELVN stock, go to TipRanks’ Stock Analysis page.